Search Results - "psoriasis"

Interleukin-17A Inhibitors in Patients with Psoriasis and Tuberculosis Infection: A 2-Year Prospective Study on Safety Without Preventive Treatment by Chun-Xia He, Chao Wu, Li Zhang, Hong-Zhong Jin

Connect to this object online.

Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study by Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Paola Facheris, Chiara Perugini, Antonio Costanzo, Alessandra Narcisi, Mario Valenti

Connect to this object online.

Safety and Efficacy of a Novel Combination Cream (GN-037) in Healthy Volunteers and Patients with Plaque Psoriasis: A Phase 1 Trial by Zafer Sezer, Ahmet Inal, Salih L. Cinar, Mustafa M. Mazicioglu, Sedat Altug, Hatice Y. Karasulu, Mine Diril, Ayca Mehmetoglu Al, Serhat Kozlu, Nadir Ulu

Connect to this object online.

Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study) by Andrea Chiricozzi, Matteo Megna, Alessandro Giunta, Carlo Giovanni Carrera, Paolo Dapavo, Anna Balato, Piergiorgio Malagoli, Stella Mazzoccoli, Aurora Parodi, Silvia Sabatino, Carlotta Buzzoni, Chu-Han Huang, Alessandra Narcisi

Connect to this object online.

Correlation between serum uric acid, C-reactive protein, and neutrophil-to-lymphocyte ratio in patients with psoriasis: A case-control study by Swayamsidda Mishra, Manjunath Kadnur, Shishira R Jartarkar, Hanumanthayya Keloji, Ritu Agarwal, Spoorthy Babu

Connect to this object online.

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative by Colombo GL, Di Matteo S, Martinotti C, Jugl SM, Gunda P, Naclerio M, Bruno GM

Connect to this object online.

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration's Adverse Event Reporting System from 2016 to 2021 by Christine Learned, BA, Sara Alsukait, MBBS, Sandhya Deverapalli, MD, MBBS, Erika Elliott, MD, Katherine Moody, MD, Jeffrey Sobell, MD, Nellie Konnikov, MD, Melissa Ortega, PharmD, David Rosmarin, MD

Connect to this object online.

Practical experience of ustekinumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to previous tumor necrosis factor blockers by Tzu-Chang Wang, Hsien-Yi Chiu, Ting-Shun Wang, Tsen-Fang Tsai

Connect to this object online.

A case of generalized psoriasis-like skin lesions caused by rituximab use in a 14-years patient with systemic lupus erythematosus by Tsymbal IN, Nikishina IP, Rodionovskaya SR, Lavrentieva IN

Connect to this object online.

IL-33/13 Axis and IL-4/31 Axis Play Distinct Roles in Inflammatory Process and Itch in Psoriasis and Atopic Dermatitis by Bodoor K, Al-Qarqaz F, Heis LA, Alfaqih MA, Oweis AO, Almomani R, Obeidat MA

Connect to this object online.

Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks by Alexander Egeberg, Lars Erik Kristensen, Luis Puig, Phoebe Rich, Saxon D. Smith, Alyssa Garrelts, Kyoungah See, Thorsten Holzkaemper, Konstantinos Fotiou, Christopher Schuster

Connect to this object online.

Digital Media Usage Behavior and Its Impact on the Physician-Patient Relationship: Cross-Sectional Study Among Individuals Affected by Psoriasis in Germany by Mert Ege Erbas, Stefanie Ziehfreund, Hannah Wecker, Tilo Biedermann, Alexander Zink

Connect to this object online.

The Benefit of the Optimized Formula of Yinxieling in Psoriasis Vulgaris via Regulation on Autophagy Based on microRNA Expression Profile and Network Pharmacology Analysis by Lu Y, Pan S, Li W, Qi Y, Li L, Yan YH, Wei J, Yao DN, Wu J, Deng H, Ye S, Chen H, Chen Q, Gao H, Han L, Lu C

Connect to this object online.

T-cell/histiocyte-rich large B-cell lymphoma in a 27-year-old with hidradenitis suppurativa, psoriasis, and vitiligo: Implications for screening by Gautham Vellaichamy, MD, Steven M. Townsend, MD, Alexis B. Lyons, MD, Iltefat H. Hamzavi, MD

Connect to this object online.

Psoriasis is associated with increased risk of other autoimmune diseases: A retrospective case-control study using the All of Us research database by Priya Marella, MBA, Shari R. Lipner, MD, PhD

Connect to this object online.

Systematic review of TNFα-induced paradoxical psoriasis: Treatment outcomes of switching to alternative biologic therapies in inflammatory bowel disease patients by Rishab Revankar, Heli Patel, Mary Rojas, Samantha Walsh, Jean S. McGee

Connect to this object online.

Psoriasis Patients with Specific HLA-Cw Alleles and Lower Plasma IL-17 Level Show Improved Response to Topical Lindioil Treatment by Lin YK, Wang CY, Huang YH, Chang YC, Chen CB, Wang CW, Hui RCY, Chung WH

Connect to this object online.

Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective by Marzieh Zargaran, Fatemeh Soleymani, Saman Ahmad Nasrollahi, Meysam Seyedifar, Mohammad Mehdi Ashrafian Rahaghi

Connect to this object online.

A Randomized Controlled Trial with a Medical Device Containing Sodium Hyaluronate and Nicotinic Acid to Increase the Efficacy of Ultraviolet Phototherapy in Psoriasis by Balázs Bende, Róbert Kui, Annamária Németh, Mariann Borsos, Zoltán Tóbiás, Gábor Erős, Lajos Kemény, Eszter Baltás

Connect to this object online.

Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study by Megna M, Ruggiero A, Tommasino N, Brescia C, Martora F, Cacciapuoti S, Potestio L

Connect to this object online.